GlassScriptPhysician profile
Jai G Parekh
NPI 1841222502
$1,951,924.29
in general payments reported to CMS, 2019-2025
46 companies · $448K in 2025
The $448K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $37K · 2021: $439K · 2022: $352K · 2023: $371K · 2024: $304K · 2025: $448K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $518K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $224K · Consulting Fee: $217K · Travel and Lodging: $87K · Food and Beverage: $45K · Honoraria: $31K · Long Term Medical Supply Or Device Loan: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $517,543.74 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $224,440.00 |
| Consulting Fee | $217,481.27 |
| Travel and Lodging | $86,561.89 |
| Food and Beverage | $45,482.55 |
| Honoraria | $31,350.00 |
| Long Term Medical Supply Or Device Loan | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $484,637.98 | 2019-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $310,415.94 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Ocular Therapeutix, INC. | $260,556.73 | 2020-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $223,858.73 | 2024-2025 | Xdemvy |
| Abbvie INC. | $188,553.04 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $149,931.99 | 2019-2025 | Cequa |
| Glaukos Corporation | $89,917.61 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idose, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Oyster Point Pharma, INC. | $48,305.45 | 2022-2025 | Tyrvaya |
| New World Medical,INC. | $35,584.26 | 2022-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Allergan, INC. | $32,217.17 | 2019-2022 | |
| Dompe US, INC. | $29,799.59 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23,931.49 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $17,940.96 | 2019-2025 | Visumax, Veracity Surgical, Clarus |
| Tearlab Corp | $10,367.47 | 2022-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Novartis Pharmaceuticals Corporation | $10,178.21 | 2019-2023 | Xiidra |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,503.07 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $4,503.94 | 2022-2023 | Tepezza |
| Beaver-Visitec International, INC. | $3,596.80 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $3,559.89 | 2020-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Biotissue Holdings INC. | $3,198.59 | 2019-2024 | |
| Thea Pharma INC. | $2,550.61 | 2024-2025 | Iyuzeh |
| Lensar, INC. | $2,400.00 | 2021-2023 | Lensar Laser System |
| Eyevance Pharmaceuticals LLC | $2,135.06 | 2019-2023 | Zerviate, Flarex |
| Lumenis Be INC | $2,000.00 | 2025 | M22 |
| Kala Pharmaceuticals, INC. | $1,932.68 | 2020-2022 | |
| Alcon Vision LLC | $1,498.20 | 2021-2025 | Rocklatan, Tryptyr, Clareon |
| Harrow Eye, LLC | $861.66 | 2024-2025 | Vevye, Iheezo |
| Rxsight INC | $416.91 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $359.22 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $322.76 | 2021-2025 | |
| Boston Scientific Corporation | $219.74 | 2023 | Watchman Flx, Avvigo Guidance System, Opticross |
| Novo Nordisk INC | $123.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $107.26 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $96.67 | 2019 | |
| Astellas Pharma US INC | $81.28 | 2025 | Izervay |
| Ivantis, INC | $78.32 | 2020 | |
| Quidel Corporation | $54.05 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $37.69 | 2023 | Tecnis Simplicity |
| Eyepoint US, INC. | $33.33 | 2021 | |
| Medtronic, INC. | $31.92 | 2024 | Corevalve Evolut R |
| Akorn, INC. | $12.77 | 2019 | |
| Shire North American Group INC | $12.25 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,595,384.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jai Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.